Annals of Surgical Oncology

, Volume 15, Issue 12, pp 3538–3549

Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines

  • Craig L. SlingluffJr
  • Galina V. Yamshchikov
  • Kevin T. Hogan
  • Sarah C. Hibbitts
  • Gina R. Petroni
  • Eric A. Bissonette
  • James W. Patterson
  • Patrice Y. Neese
  • William W. Grosh
  • Kimberly A. Chianese-Bullock
  • Andrea Czarkowski
  • Patrice K. Rehm
  • Jayashree Parekh
Melanomas

DOI: 10.1245/s10434-008-0046-4

Cite this article as:
Slingluff, C.L., Yamshchikov, G.V., Hogan, K.T. et al. Ann Surg Oncol (2008) 15: 3538. doi:10.1245/s10434-008-0046-4

Abstract

Background

We hypothesized that lymph nodes draining sites of cutaneous vaccination could be identified by sentinel node biopsy techniques, and that measuring T-cell response with lymphocytes obtained from these lymph nodes would provide a more sensitive measure of immunogenicity than would the same measurement made with peripheral blood lymphocytes (PBL).

Methods

ELISpot analysis was used to determine the magnitude of vaccine-specific T-cell response in the sentinel immunized nodes (SIN), random lymph nodes, and peripheral blood lymphocytes (PBL) obtained from patients enrolled in clinical trials of experimental melanoma vaccines.

Results

The SIN biopsy was successful in 97% of cases and morbidity was very low. The T-cell response to vaccination was detected with greater sensitivity in the SIN (57%) than in PBL (39%), and evaluation of T-cell responses in the SIN and the PBL together yielded T-cell responses in 63% of patients. When the T-cell responses from a SIN and a random lymph node were compared in four patients, immune responses were detected to one of the vaccine peptides in three of these four patients. In all of those cases, responses were present in the SIN but absent from the random lymph node.

Conclusion

Measurements of T-cell responsiveness to cutaneous immunization are more frequently positive in the SIN than they are in the PBL, however evaluation of both the SIN and PBL permit a more sensitive measure of T-cell immunogenicity than use of either single source.

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Craig L. SlingluffJr
    • 1
    • 2
  • Galina V. Yamshchikov
    • 1
    • 2
  • Kevin T. Hogan
    • 1
    • 2
  • Sarah C. Hibbitts
    • 1
    • 2
  • Gina R. Petroni
    • 2
    • 3
  • Eric A. Bissonette
    • 3
  • James W. Patterson
    • 2
    • 4
  • Patrice Y. Neese
    • 1
    • 2
  • William W. Grosh
    • 2
    • 5
  • Kimberly A. Chianese-Bullock
    • 1
    • 2
  • Andrea Czarkowski
    • 1
    • 2
  • Patrice K. Rehm
    • 6
  • Jayashree Parekh
    • 6
  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of VirginiaCharlottesvilleUSA
  2. 2.Human Immune Therapy CenterUniversity of VirginiaCharlottesvilleUSA
  3. 3.Department of Health Evaluation SciencesUniversity of VirginiaCharlottesvilleUSA
  4. 4.Department of PathologyUniversity of VirginiaCharlottesvilleUSA
  5. 5.Division of Hematology–Oncology, Department of MedicineUniversity of VirginiaCharlottesvilleUSA
  6. 6.Department of RadiologyUniversity of VirginiaCharlottesvilleUSA